Lipid and Lipoprotein Disorders

References References 1. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study - Implications for LDL management. J Clin Lipidol. 2007;1(6):583-592. 2. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol. Oct 17, 2002;90(8A):22i-29i. 3. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. Mar 2009;55(3):407-419. 5. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC, Jr. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. Mar-Apr 2011;5(2):105-113. 4. Cromwell WC, Barringer TA. Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep. Nov 2009;11(6):468-475. 6. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. Am J Cardiol. Dec 15, 2006;98(12):1599-1602. 7. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Despres JP, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol. May 15, 2003;91(10):1173-1177. 8. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. J Clin Lipidol. Sep 2011;5(5):338-367. 9. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness. Circulation. January 30, 2007;115(4):459-467. 10. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. Jul 13, 2004;110(2):227-239. 11. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. Feb 14, 2007;297(6):611-619. 12. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. Nov 25, 2008;118(22):2243-2251, 2244p following 2251. 13. McClelland RL, Nasir K, Budoff M, Blumenthal RS, Kronmal RA. Arterial age as a function of coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. Jan 1, 2009;103(1):59-63. 14. Greenland P, Bonow RO, Brundage BH, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. Jan 23, 2007;49(3):378-402. 15. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age. Circulation. February 14, 2006;113(6): 791-798. 16. Mottillo S, Filion KB, Genest J, et al. The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and Meta-Analysis. J Am Coll Cardiol. September 28, 2010;56(14): 1113-1132. 17. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. May-Jun 2011;5(3):133-140. 24

• Cover